Tarsus Announces Proposed $50 Million Underwritten Public Offering of Shares of its Common Stock
May 02 2022 - 7:01AM
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) (the “Company” or
“Tarsus”), whose mission is to focus on unmet needs and apply
proven science and new technology to revolutionize treatment for
patients, starting with eye care, today announced the commencement
of an underwritten public offering of $50 million of shares of its
common stock. Tarsus also expects to grant the underwriters a
30-day option to purchase an additional 15% of the shares of
its common stock. The offering is subject to market and other
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering. All of the shares in the proposed offering are to be sold
by Tarsus.
BofA Securities, Jefferies, Barclays and Raymond James are
acting as joint book-running managers for the offering. LifeSci
Capital is acting as lead manager for the offering.
A preliminary prospectus supplement related to the offering
(including the accompanying prospectus) will be filed with the SEC
and will be available on the SEC’s website located
at www.sec.gov. Copies of the preliminary prospectus
supplement and the accompanying prospectus may also be obtained,
when available, from BofA Securities, NC1-004-03-43, 200 North
College Street, 3rd floor, Charlotte, NC 28255-0001, Attn:
Prospectus Department, or via email at
dg.prospectus_requests@bofa.com; Jefferies by telephone at
1-877-821-7388 or by email at prospectus_department@jefferies.com;
Barclays, c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, by telephone at 1-888-603-5847 or by
email at barclaysprospectus@broadridge.com; and Raymond James at
1-800-248-8863 or by email at prospectus@raymondjames.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction. Any offer, if at all, will be made only by
means of a final prospectus supplement and accompanying prospectus
forming a part of the effective registration statement.
About Tarsus Pharmaceuticals, Inc.Tarsus
Pharmaceuticals, Inc. applies proven science and new technology to
revolutionize treatment for patients, starting with eye care. It is
advancing its pipeline to address several diseases with high unmet
need across a range of therapeutic categories, including eye care,
dermatology, and infectious disease prevention. The company is
studying two investigational medicines in clinical trials. Its lead
product candidate, TP-03, is a novel therapeutic which has
demonstrated positive results in two pivotal trials for the
treatment of Demodex blepharitis. TP-03 is also being developed for
the treatment of Meibomian Gland Disease. In addition, Tarsus is
developing TP-05, an oral, non-vaccine therapeutic for the
prevention of Lyme disease, which is currently being studied in a
Phase 1b clinical trial.
Forward-Looking StatementsStatements in this
press release about future expectations, plans and prospects, as
well as any other statements regarding matters that are not
historical facts, may constitute “forward-looking statements.” The
words, without limitation, “believe,” “contemplate,” “continue,”
“could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,” or
“would,” or the negative of these terms or other similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these or
similar identifying words. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors; including, but not limited to, risks
and uncertainties related to market conditions and satisfaction of
customary closing conditions related to the proposed public
offering. Further, there are other risks and uncertainties
that could cause actual results to differ from those set forth in
the forward-looking statement and they are detailed from time to
time in the reports Tarsus files with the Securities and Exchange
Commission, including Tarsus’ Form 10-K for the year ended December
31, 2021 filed on March 14, 2022 with the SEC, which Tarsus
incorporates by reference into this press release, copies of which
are posted on its website and are available from Tarsus without
charge. However, new risk factors and uncertainties may emerge from
time to time, and it is not possible to predict all risk factors
and uncertainties. Accordingly, readers are cautioned not to place
undue reliance on these forward-looking statements. Any
forward-looking statements contained in this press release are
based on the current expectations of Tarsus’ management team and
speak only as of the date hereof, and Tarsus specifically disclaims
any obligation to update any forward-looking statement, whether as
a result of new information, future events or otherwise.
Contacts: Media Contact:Adrienne KempSr.
Director, Corporate Communications(949)
922-0801akemp@tarsusrx.com
Investor Contact:David NakasoneHead of Investor Relations(949)
620-3223DNakasone@tarsusrx.com
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Apr 2024 to May 2024
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From May 2023 to May 2024